Clinical Trial Update: Safety and Tolerability of Glatiramer Acetate [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and tolerability of glatiramer acetate in Relapsing-Remitting Multiple Sclerosis has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GLATIRAMER ACETATE (GLATIRAMER ACETATE)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2016-01-14